Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

April 14, 2020; 94 (15 Supplement) Tuesday, April 28

Hidden in plain sight: a rationale for repurposing apomorphine in addiction disorders (1529)

Manon Auffret, Marc Verin, Andrew Lees
First published April 14, 2020,
Manon Auffret
1EA 4712, University of Rennes 1
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Verin
1EA 4712, University of Rennes 1
2Neurology, CHU Hopital Pontchaillou
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Lees
3Reta Lila Weston Institute of Neurological Studies, IoN, UCL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Hidden in plain sight: a rationale for repurposing apomorphine in addiction disorders (1529)
Manon Auffret, Marc Verin, Andrew Lees
Neurology Apr 2020, 94 (15 Supplement) 1529;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To investigate the potential role of apomorphine as a treatment for addiction disorders.

Background: 19.7 million American adults suffered from a substance abuse disorder in 2017 (National Survey on Drug Use and Health). To date, effective treatment for addiction is still lacking, and many of the programs often fail to keep patients drug-free. Considering the health, social and economic burden of addiction, new strategies are needed. Drug repurposing may be one option, with candidates such as apomorphine. Currently prescribed in Parkinson’s disease, apomorphine has already been used as a treatment for addiction, mainly to alcohol (but also opiates), between the beginning of the 20th century and the late 1970’s. If aversion therapy was the most common approach, some clinicians suspected another action, based on possible anti-craving properties.

Design/Methods: A nonsystematic database (PubMed, Google Scholar, JSTOR, Internet Archive, BnF Gallica) search for French and English articles related to the use of apomorphine in addiction (regardless of the type) was undertaken.

Results: Several historical reports (starting as early as 1899) suggest that apomorphine may play a role in relieving alcoholic craving. These empirical assumptions are supported by recent data from animal models. The dopaminergic and serotonergic (5-HT1 & 5-HT3 receptors) systems, both involved in alcohol dependence, are targeted by apomorphine stimulation. Apomorphine upregulates NGF and GDNF synthesis in cell cultures: these neurotrophic factors are known to modulate addictive behavior. Additionally, apomorphine displays neuroprotective properties against ethanol-induced neurodegeneration in the adult rat cortex. Finally, a recent review on smoking cessation suggested that apomorphine might be a useful treatment.

Conclusions: There is now a considerable body of both historical and neuromolecular evidence to support further research studying the role of apomorphine in addiction.

Disclosure: Dr. Auffret has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Britannia, EverPharma. Dr. Auffret has received research support from France Développement Electronique (FDE), Homeperf, LVL. Dr. Verin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Britannia. Dr. Verin has received research support from Homeperf, LVL, FDE. Dr. Lees has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Britannia Pharmaceuticals, Profile Pharma, UCB, Roche, BIAL, STADA, Nordiclnfu Care, and NeuroDerm. Dr. Lees has received personal compensation in an editorial capacity for Britannia Pharmaceuticals- kinetic Journal.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Safety and Efficacy of Tenecteplase and Alteplase in Patients With Tandem Lesion Stroke: A Post Hoc Analysis of the EXTEND-IA TNK Trials

Dr. Nicole Sur and Dr. Mausaminben Hathidara

► Watch

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 100 (22)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise